Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 07, 2023
Lead Product(s) : 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : RNAcure Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : RNAcure Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : RNAcure Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : RNAcure Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZR-202-CoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Shanghai Zerun Biotechnology Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 06, 2022
Lead Product(s) : ZR-202-CoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Shanghai Zerun Biotechnology Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mexico to Start Late-Stage Clinical Trial for China's mRNA COVID-19 Vaccine
Details : ARCoV or ARCoVax, China's first mRNA vaccine to enter Phase III trials, jointly developed by the People's Liberation Army (PLA) Academy of Military Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology Co., Ltd.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : SARS-CoV-2 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 202-CoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Shanghai Zerun Biotechnology Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 04, 2021
Lead Product(s) : 202-CoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Shanghai Zerun Biotechnology Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 202-CoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Shanghai Zerun Biotechnology Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 29, 2021
Lead Product(s) : 202-CoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Shanghai Zerun Biotechnology Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STP702
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Sirnaomics
Deal Size : $6.4 million
Deal Type : Partnership
Details : The partnership will specifically focus on development of the siRNA-based anti-influenza therapeutic candidate STP702. Walvax will get an exclusive development and commercialization rights for territories including mainland China, Taiwan, Hong Kong and M...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 29, 2021
Lead Product(s) : STP702
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Sirnaomics
Deal Size : $6.4 million
Deal Type : Partnership
Lead Product(s) : SARS-CoV-2 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Suzhou Abogen Biosciences | Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 15, 2021
Lead Product(s) : SARS-CoV-2 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Suzhou Abogen Biosciences | Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable